Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients
Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients
复制标题
DOI：
10.1007/s11255-021-02952-1
复制
发表时间：
2021-07-15
影响因子：
2
通讯作者：
Oya，Mototsugu
中科院分区：
文献类型：
--
作者：
Yoshida，Tadashi;Morimoto，Kohkichi;Oya，Mototsugu
目的铁系磷结合剂包括柠檬酸铁水合物（FCH）和氢氧化蔗糖铁（SFOH），已被用于治疗终末期肾病透析患者的高磷血症。然而，长期的有效性和安全性，这些代理商尚未明确delayed.MethodsLaboratory数据的56例血液透析患者已规定FCH（n= 33）或SFOH（n= 23）进行了回顾性examined.ResultsWe表明，FCH和SFOH显着和一贯降低血清磷酸盐浓度在36个月的观察期内进行维持性血液透析的患者。血清钙水平、全段甲状旁腺激素以及血红蛋白水平均未改变。铁代谢参数，如转铁蛋白饱和度和血清铁蛋白水平，没有观察到过冲，血清铁蛋白水平在大多数患者中保持在300 ng/mL以下。在两个治疗组中均观察到所用红细胞生成刺激剂剂量和静脉铁剂使用频率降低的趋势。在接受FCH或SFOH的患者中没有观察到严重的药物不良反应。ConclusionThe结果表明，铁基磷结合剂，FCH和SFOH，降低血清磷浓度一致，是安全的，长期使用在维持性血液透析患者。
PurposeIron-based phosphate binders, including ferric citrate hydrate (FCH) and sucroferric oxyhydroxide (SFOH), have been used for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. However, the long-term efficacy and safety of these agents have not yet been clearly elucidated.MethodsLaboratory data of 56 hemodialysis patients who had been prescribed either FCH (n= 33) or SFOH (n= 23) were retrospectively examined.ResultsWe showed that both FCH and SFOH significantly and consistently decreased serum phosphate concentrations in the patients undergoing maintenance hemodialysis during the 36-month observation period. Serum levels of calcium, intact parathyroid hormone, as well as hemoglobin levels were unaltered. No overshoot of parameters of iron metabolism, such as transferrin saturation and serum ferritin levels, was observed, and serum ferritin level remained under 300 ng/mL in most patients. A trend towards decrease in the doses of erythropoiesis-stimulating agents used and frequency of intravenous iron use was observed in both treatment groups. No severe adverse drug reactions were observed in either the patients receiving FCH or SFOH.ConclusionThe results of the present study suggest that the iron-based phosphate binders, FCH and SFOH, decrease serum phosphate concentrations consistently and are safe to use over the long-term in maintenance hemodialysis patients.